MedTrace Logo

Biological Age in Children With GH Deficiency Undergoing Hormone Replacement Therapy

NCT06294860 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2025-09-03

No results posted yet for this study

Summary

The primary objective of the study is to evaluate the epigenetic age in children with GH deficiency, before and after 6 months of treatment with growth hormone replacement therapy. The secondary objective is to correlate the epigenetic age with the auxometric and biochemical parameters used in the clinical-endocrinological practice. The results of the study will be useful to set up the clinical and biochemical follow-up of the hormone replacement therapy with rhGH and to understand the biomolecular mechanisms at the base of the debated "anti" or "pro" aging action of GH, the most important anabolic hormone of the human organism.

Conditions

  • Growth Hormone Deficiency
  • Short Stature

Sponsors & Collaborators

  • Istituto Auxologico Italiano

    lead OTHER

Principal Investigators

  • Alessandro Sartorio, MD · Istituto Auxologico Italiano

Eligibility

Min Age
5 Years
Max Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-19
Primary Completion
2025-03-30
Completion
2025-03-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06294860 on ClinicalTrials.gov